Please login to the form below
Ovid
This page shows the latest Ovid news and features for those working in and with pharma, biotech and healthcare.
Ovid wins Communiqué Small Consultancy of the Year award at Communiqué 2021
Ovid took home the Communiqué Small Consultancy of the Year award at the 2021 Communiqué Awards held on 1 September at the Grosvenor House hotel in London. ... Jenny Ousbey, Founder and MD of OVID Health said: “We were absolutely thrilled to win this
Latest news
-
McCann Health, Dovetail, Evoke and Oxford PharmaGenesis among big winners at Communiqué Awards
Winner OVID Health. See the full list of winners here.
-
Biotech leaders jump into US free speech debate
Alnylam chief executive John Maraganore, Decibel Therapeutics’ CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but
-
Biotech leaders slam Trump over immigration order
The long list of signatories is headed by Jeremy Levin, former CEO of Teva who is now heading up Ovid Therapeutics.
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2017
But it was not all inward traffic with the company announcing a global collaboration with Ovid to jointly develop and commercialise Takeda's selective CH24H inhibitor TAK-935 for the treatment
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Roudie Shafie joins OVID Health’s senior team as director
Independent specialist healthcare agency OVID Health has appointed healthcare and pharma industry veteran Roudie Shafie as its new director. ... I look forward to playing a big role in establishing OVID as the go-to agency for inventive campaigns in
-
Ovid Therapeutics adds member to scientific advisory board
Ovid is a privately-held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain. ... He said: “Ovid is pursuing an ambitious approach of tackling rare neurological diseases with significant unmet needs.
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
OPEN Health’s virtual reflections on the World Orphan Drug Congress US
To paraphrase Luke Rosen from OVID and KIF1A – in the context of clinical trial protocol: to ask for feedback on a protocol equates to failure.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
